Sei sulla pagina 1di 14

Annual Report 2009-2010

Haematology

Haematology
he Department of Haematology functions both as a major clinical and laboratory medicine department. It plays a pivotal role in the teaching of haematology to undergraduate medical students (MD), postgraduate students of medicine who have opted to specialise in medicine, and Oman Medical Specialty Board (OMSB) residents in haematology, as well as medical laboratory technicians in the B.Sc. Medical Laboratory Sciences course. Our laboratory provides state of the art haematology testing for the University Hospital (SQUH) and referral services to other private hospitals, as well as highly specialised testing such as flowcytometric and molecular haematological analysis for haematological condition diagnostics for the whole of Oman.

86

Fehmida Zia, Registrar Fauzia Wasim, Registrar Abdulmanan Adulgafoor, Registrar Mehwesh Taj, Registrar Vinodh Panjwani, Senior House Officer Najwa Abdulhameed, Senior House Officer Ghasan Ageed, Senior House Officer Mohamed Rehan, Senior House Officer Moez HA Rhim, Senior House Officer

Support Staff

Dr. Sa lam Al- Kin di


Head of Department

Staff
Faculty
Chao Hung Ho, Professor Shahina Daar, Associate Professor David Dennison, Senior Consultant Anil Pathare, Senior Consultant Naglaa Fawaz, Senior Consultant Mohammad Huneini, Consultant Khalil Al-Farsi, Consultant Murtadha Al-Kabori, Consultant Nadeem Nusrut, Senior Registrar Zeba Zabeen, Senior Registrar Hammad Khan, Senior Registrar

academic and patient care departments

87

Haematology

Stuart Donaldson, Superintendent David Gravell, Chief Biomedical Scientist Heidi M. Davis, Chief Biomedical Scientist Shakila Ashraf, Senior Biomedical Scientist Ali Al-Marhoobi, Senior Biomedical Scientist Hamood Al-Haddabi, Senior Biomedical Scientist Rodrigo Villacrusis, Senior Biomedical Scientist Maria Cicillia, Senior Biomedical Scientist Abdulrehman N. Rashid, Senior Biomedical Scientist Qamariya Al-Abri, Biomedical Scientist Mariyam Al-Brashdi, Biomedical Scientist Sabah Al-Mahrooqi, Biomedical Scientist Sahima Al-Mamari, Biomedical Scientist Saif Al-Hosni, Biomedical Scientist Hamed Al-Gheithi, Biomedical Scientist Shoaib Al-Zadjali, Biomedical Scientist Sumaya Al-Hinani, Biomedical Scientist Asma A. Musleh, Biomedical Scientist Karima Al-Falahi, Biomedical Scientist Badriya Al-Belushi, Biomedical Scientist Bushra Al-Said, Biomedical Scientist Mohammed Al-Rawahi, Biomedical Scientist Muna Al-Maskari, Biomedical Scientist Ishaq Al-Salmi, Biomedical Scientist Deuel M. Labrador, Biomedical Scientist

Annual Report 2009-2010


Haematology
Enrique O. Pedojan, Biomedical Scientist Eufrosina Alverez, Biomedical Scientist Julian Neson, Biomedical Scientist Mohan Doraiswamy, Biomedical Scientist Nestor Naniong, Biomedical Scientist Rene Gabucay, Biomedical Scientist Allan S. Aurelio, Biomedical Scientist Adela Angeles, Biomedical Scientist Melani Tauro, Biomedical Scientist Malvin J. Wee Li, Biomedical Scientist Vardarajan Nelvoy, Biomedical Scientist Lancy Henry, Biomedical Scientist Rhea Misquith, Biomedical Scientist Rosamma Soney, Head Staff Nurse Binny Sam, Senior Staff Nurse Rose Saly, Staff Nurse 2 Mary Kurian, Staff Nurse - ICH3 Victoria G Menezes, Staff Nurse 2 Shiney Thomas, Staff Nurse 2 Salva Kumari, Staff Nurse 2 Bindu Shiby, Staff Nurse 2 Eman Al-Homaidi, Coordinator Tomichan Varghese, Coordinator Ibrahim Al-Amri, Coordinator

Highlights of the Year 2009-2010

In 20092010, the clinical unit treated patients with a vast range of haematological disorders, both as inpatients and outpatients. In addition, the Department runs a thalassaemia day care unit. In 2010, it offered comprehensive care for about 142 patients with transfusion dependent thalassaemia. Of national interest is the successful bone marrow transplant programme, run by this department. By the end of Dec. 2010, a total of 175 allogeneic bone marrow transplants had been performed in this centre, with results as good as those from the best centres around the world.

88

Teaching Programmes
UN D ER G R AD U AT E P R O GR A M M E
In this period the Department has: 1) participated in teaching the Haemato-Lymph-Vascular course to the third year students; 2) developed and taught a new module in phase 2 of the undergraduate curriculum on hemato-lymphatic-immunology; 3) participated and coordinated the various courses in phase 2 of the new curriculum, in particular Integrated modules I, II, III; 4) run a 5 week course on case-based learning, in Haematology for the 5th year students in the Integrated Lecture Series (ILS); 5) participated in bedside clinical teaching in Medicine; 6) run Laboratory rotations for 6 groups of 7th year students, each rotation of 5 days duration; 7) run a B.Sc MLS degree course for training undergraduate biomedical scientists.

P O ST G R AD U AT E PR O GR A M M E

The Department has developed and taught the Haematopathology course along with the Ministry of Health Royal Hospital, which is affiliated with the Oman Medical Specialty Board. There are 6 residents at various stages of training in the programme.

Clinical & Diagnostic Services

BO N E MAR R O W T R A NS P L A NT A T IO N P R O GR A M M E

S IC K LE C ELL PR O GR A M M E

The Department looks after a large number of patients with sickle cell disease (SCD) providing acute medical care, as well as genetic counselling and preventive programmes (vis--vis cord blood testing), and organising and guiding the patients and the medical community in the care of SCD. Recently the role of the Department

89

Haematology

The bone marrow transplant programme, established in 1995 in the Department, serves the entire country and continues to provide curative treatment for patients with haematologic malignancy, bone marrow failure and potentially fatal genetic diseases. In 2010, 22 transplants were performed, making a total of 175 transplants since 1995. The results of this transplant centre are comparable with those of the best centres worldwide. Importantly, the cost per transplant is a fraction of what is charged in other countries.

academic and patient care departments

The clinical services centre on the following major areas; adult outpatients, adult inpatients; bone marrow transplantation, sickle cell anaemia programe; the leukaemia, lymphoma and myeloma programme, and the thalassaemia day care unit. The laboratory services likewise cover specialised areas: haemostasis, flowcytometry, haemoglobinopathy, molecular diagnostics, general laboratory haematology and the blood transfusion service which includes blood donation, storage, irradiation, plasmapheresis and exchange and apheresis facilities as well as the blood grouping and cross matching laboratory.

Annual Report 2009-2010


Haematology
has been highlighted through our community outreach programmes via the Hereditary Blood Disorders Society.

L EUK AEMI A LYMPH OM A A ND M Y E L O M A P R O GR A M M E

The Department is now an important tertiary care centre for most referrals for adult haematological malignancies particularly leukaemias, and myeloma. Our patients are able to receive state-of-the-art care both in terms of diagnostic and therapeutic modalities, including bone marrow transplant (BMT) and the advanced molecular diagnostics needed for proper follow-up.

TH ALASSAEMI A U N I T

The Department has been looking after about 150 patients with thalassaemia, delivering comprehensive care including blood transfusions, chelation therapy, and regular meticulous monitoring for the side effects and complications of the disease and its treatment. The unit is a centre of excellence in the region with heavy involvement in care and research including participation in an international drug trial (Exjade). The unit has recently acquired the latest state of art MRI T2* equipment for monitoring the cardiac and liver iron overload status which has improved the monitoring of iron overload in these patients.

H AE MAT O LO G Y C LI N ICS A T T HE NE W S O HA R HO S P IT A L

The Department conducts a monthly haematology clinic at the new Sohar Hospital. The clinic is run on rotation basis by one of the Departments haematology consultants. They are assisted locally by Dr Ali AlMadhani, from the Department of Medicine, Sohar Hospital.

GEN ER AL LAB O R AT OR Y S E R V ICE S

The Haematology Laboratory caters to the entire hospital and additionally receives referral samples from all over Oman for routine and advanced haematology laboratory testing. The laboratory is subdivided into various sections including general haematology, haemoglobinopathy, haemostasis and special haematology, blood banking and donor room services, and the molecular division.

M OLEC U LAR R ESEAR CH A ND D IA GNO S T IC L A B O R A T O R Y

The Department now offers DNA diagnostic facilities for several thrombophilic disorders, haemoglobin disorders, immune deficiency syndromes and malignant haematology, especially for acute and chronic leukaemia. The section is also involved in the monitoring of the transplant progress by chimerism studies in post-transplant patients.

90

CO R D B LO O D B AN K

The Department, in collaboration with the Department of Obstetrics & Gynaecology, has now set up a Cord Blood Bank. We have standardised the collection and storage of cord blood samples. Collection of cord blood is currently done under two programs: a) sibling cord blood (SCB) and, b) unrelated cord blood (UCB). Up to August 2010, we had collected a total of 73 SCB units and 41 UCB units. We have so far used 3 SCB units for sibling cord blood transplantation.

A PH ER ESI S U N I T O F T HE B L O O D B A NK

The Department has now installed the Baxter Amicus and Cobe Spectra apheresis systems and our apheresis nurses and technicians are trained in their use. Both of these systems are now in routine use for harvesting stem cells from donors in the Departments Bone Marrow Transplantation program and platelet apheresis. Moreover, apheresis services are now made available, in consultation with the attending haematologist on duty, to the SQUH wards and ICU units whenever the need for plasmapheresis or plasma exchange arises.

BU SU LPH AN PH AR M A K O K INE T ICS

Optimisation of busulphan dosage in patients undergoing bone marrow transplantation is recommended in order to reduce the toxic effects associated with high drug levels. The API 150 EX LCMS system which has been installed for the research project on intravenous versus oral busulphan in BMT for thalassaemia is now fully operational. The section looks after the busulphan pharmakokinetics in patients undergoing BMT to assess the blood levels of the drug in order to optimise the treatment protocols.

Table 1: Haematology Laboratory Activities


Year Jan-Dec 2007 2008 2009 2010 11,7631 14,7799 17,7568 19,8109 Number of Patients % increase over last year -12.1% +25.6% +20.1% +11.6% Tests & Procedures % Change on previous year -2.5% +23.3% +19.1% +9.3%

48,5060 59,8309 71,2520 77,8662

academic and patient care departments

91

Haematology

Annual Report 2009-2010


Haematology

Table 2: Clinical Workload


Year Jan-Dec 2007 2008 2009 2010 Haematology Inpatients 1416 1409 1887 1869 % Change on Previous Year +5.3% -0.5% +33.9% -1.0% Haematology Day Care 3078 3035 3127 3271 % Change on Previous Year -10.5% -1.4% +3.0% +4.6% Haematology Outpatients 2826 3428 4181 4407 % Change on Previous Year +6.2% +21.3% +22.0% +5.4%

Research
RES EAR C H PR O JEC TS
Establishment of a national facility in stem cell translation research for novel cellular-based therapies and tissue repair Project Code: Value: Investigators: SR/MED/ HAEM/09 /01; Dates: 20092011 OR 165,000; Project Funder: His Majestys Strategic Fund, Oman Dr. David Dennison, Dept. Haematology, SQU; Dr. Sultan Al-Maskari Dept. Surgery, SQU; Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Salam Al-Kindi, Dept. Haematology, SQU; Dr. Khalil Al-Farsi, Dept. Haematology, SQU; Dr. Mohammed Al-Hunieni, Dept. Haematology, SQU; Dr. Nagla Fawaz, Dept. Haematology, SQU; Ms. Qamariya Al-Abri, Dept. Haematology, SQU; Ms. Sahima Al-Maamaari, Dept. Haematology, SQU; Ms. Sabah Al-Mahrooqi, Dept. Haematology, SQU; Ali Al-Mahroobi, Dept. Haematology, SQU; Hamed Al-Gheiti, Dept. Haematology, SQU; Shoaib Al-Zadjali, Dept. Haematology, SQU; Melanie Tauro, Dept. Haematology, SQU; Dr. Yasser Wali, Dept. Child Health, SQU; Dr. Abdulhakeem Rawas, Dept. Child Health, SQU; Dr. Muhanna Al-Muslahi, Dept. Haematology, Royal Hospital, Oman ; Dr. Hamoud Al-Dhuli, Dept. Radiology, SQU; Dr. Rashid Al- Sukaiti, Dept. Radiology & Molecular Imaging, SQU; Dr. Shyam Ganguly, Dept. Family Medicine & Public Health, SQU; Dr. Helmut Schuster, Dept. Microbiology & Immunology, SQU; Dr. Adeeb Al-Zoubi, Jordan University, Jordan.

92

Molecular Genetics of alpha globin gene expression in native Omani Population: Towards understanding the molecular basis of alpha thalassaemia and impact on clinical expression of beta thalassaemia and sickle cell disease Project Code: RC/MED/HAEM/10/01; Dates: 2010-2012 Value: Investigator: OR 68,300; Project Funder: The Research Council, Oman Dr. Salam Al-Kindi, Dept. Haematology, SQU; Dr. Muhammed Al-Hunaini, Dept. Haematology, SQU; Dr. Khalil Al-Farsi, Dept. Haematology, SQU; Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Nagla Fawaaz, Dept. Haematology, SQU; Shoaib Al-Zadjali, Dept. Haematology, SQU; Hamood Al-Haddabi, Dept. Haematology, SQU; Dr. R. Krishnamoorthy, INSERM U 763, Paris, France.

Pharmacogenomic factors affecting warfarin dosing: Rationale for prospective genetic screening before anticoagulation therapy Project Code: IG/MED/HAEM/09/01; Dates: 20092010 Value: Investigator: OR 5,400; Project Funder: Sultan Qaboos University Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Salam Al-Kindi, Dept. Haematology, SQU; David Gravell, Dept. Haematology, SQU; Shoaib Al-Zadjali, Dept. Haematology, SQU; Hamood Al-Haddabi, Dept. Haematology, SQU; Dr. R. Krishnamoorthy, INSERM U 763, Paris, France.
academic and patient care departments

Genetic basis of variable expression of fetal hemoglobin in sickle cell disease and beta thalassaemia patients from Oman Project Code: IG/MED/HAEM/10/01; Dates: 20102011 Value: Investigator: OR 4,700; Project Funder: Sultan Qaboos University Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Salam Al-Kindi, Dept. Haematology, SQU; Mohammed Al-Hunieni, Dept. Haematology, SQU; Dr. Khalil Al-Farsi, Dept. Haematology, SQU; Dr. Shahina Daar, Dept. Haematology, SQU; Shoaib Al-Zadjali, Dept. Haematology, SQU; Sahima Al-Maamari, Dept. Haematology, SQU; Dr. R. Krishnamoorthy, INSERM U 763, Paris, France.

Safety profile and therapeutic use of back ink from Omani fishes in two experimental models of osteoporosis in rats Project Code: IG/MED/HAEM/10/02; Dates: 20102011 Value: Investigators: OR 11,500; Project Funder: Sultan Qaboos University Dr. Haddia Berehi, Dept. Medical Physics, SQU; Prof. Badreldin Ali, Dept.

93

Haematology

Annual Report 2009-2010


Haematology
Pharmacology & Clinical Pharmacy, SQU; Dr. Kamran Malik, Dept. Surgery, SQU; Dr. Khaled Malgat, Dept. Chemistry, SQU; Dr Aisha Al-Hamadani, Dept. Pathology, SQU. Role of von Willebrand factor on the occurrence of vaso-occlusive crisis in patients with sickle cell disease. Project Code: Value: Investigator: IG/MED/ HAEM/10/02; Dates: 20102012 OR 11,500; Project Funder: Sultan Qaboos University Mohammed Al-Hunieni, Dept. Haematology, SQU; Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Prof. Ho Chao-Hung, Dept. Haematology, SQU; David Gravell, Dept. Haematology, SQU; Shoaib Al-Zadjali, Dept. Haematology, SQU; Qamariya Al-Abri, Dept. Haematology, SQU; Vinod Panjwani, Dept. Haematology, SQU; Hamed Khan, Dept. Haematology, SQU. MREC #325; Dates: 201011 Dr. Shahina Daar, Dept. Haematology, SQU, Dr. Samir Hussein, Dept. Radiology & Molecular Imaging, SQU, Mohammed Al-Hunieni, Dept. Haematology, SQU.

Prevalence of abnormal bone densitometry findings in individuals with homozygous beta thalassaemia Project Code: Investigators: Value: Unfunded; Project Approval: Sultan Qaboos University

Prevalence of optimal monitoring of kidney function in relation to patients with thalassaemia. Project Code: Investigators: MREC #351 Dates: 20102011 Dr. Shahina Daar, Dept. Haematology, SQU; Dr. Sunil Bhandari, Hull York Medical School, UK; Dr. Khalid Al-Rasadi, Dept. Biochemistry, SQU; Humoud Al-Dhuhli, Dept. Radiology & Molecular Imaging, SQU; Surekha Mevada, Dept. Child Health, SQU; Dr Hammad Khan, Dept. Haematology, SQU. MREC #361; Dates: 20102011 Dr. Shahina Daar, Dept. Haematology, SQU; Humoud Al-Dhuhli, Dept. Radiology & Molecular Imaging, SQU. Value: Unfunded; Project Approval: Sultan Qaboos University

Evaluation of cardiac and liver iron load by MRI T2* Project Code: Investigators: Value: Unfunded; Project Approval: Sultan Qaboos University

94

Prevalence of endocrinopathies in thalassaemia major patients, correlation with total body iron load and cardiac iron load Project Code: Investigators: MREC #344; Dates: 20102011 Dr. Shahina Daar, Dept. Haematology, SQU; Dr Khalil Al Farsi, Dept. Haematology, SQU; Dr. David Dennison, Dept. Haematology, SQU; Dr Fehmida Zia, Dept. Haematology, SQU; Dr Moez HA Rhim Dept. Haematology, SQU. Value: Unfunded; Project Approval: Sultan Qaboos University

Clinical effects of Nicosan TM to reduce the occurrence vasoocclusive crisis patients with sickle cell disease Project Code: Investigators: MREC# 352; Dates: 2010 Dr. Salam Al Kindi, Dept. Haematology, SQU Value: Unfunded; Project Approval: Sultan Qaboos University Retrospective analysis of Sickle cell patient with PORT-A-CATH insertion to analyze complications of PORT-A-CATH in patients with Sickle cell Disease Project Code: Investigators: MREC# 357; Dates: 2010 Dr. Salam Al Kindi, Dept. Haematology, SQU
academic and patient care departments

Value: Unfunded; Project Approval: Sultan Qaboos University Evaluation of Cardiac and Liver Iron Load by Cardiac MRI (T2*) Project Code: MREC# 361; Dates: 2010 Value: Unfunded; Project Approval: Sultan Qaboos University Investigators: Dr. Shahina Daar, Dept. Haematology, SQU MREC# 362; Dates: 2010 Dr. Khalil Al Farsi, Dept. Haematology, SQU MREC# 363; Dates: 2010 Causes and Outcome of Fever in patients with Sickle cell Disease Project Code: Investigators: Value: Unfunded; Project Approval: Sultan Qaboos University Acute Chest Syndrome in Sickle Cell Patients during Pregnancy: Risk Factors and Outcome Project Code: Value: Unfunded; Project Approval: Sultan Qaboos University

95

Haematology

Annual Report 2009-2010


Haematology
Investigators: Dr. Khalil Al Farsi, Dept. Haematology, SQU. MREC# 364; Dates: 2010 Dr. Khalil Al Farsi, Dept. Haematology, SQU.

Causes of Prolonged Prothrombin Time and Activated Partial Thromboplastin Time Project Code: Investigators: Value: Unfunded; Project Approval: Sultan Qaboos University

RES EAR C H PU B LI C ATIO NS & B O O K S


Journal Publications
1. 2. Pathare AV, Taher A, Daar S. Deferasirox (Exjade(R)) significantly improves cardiac T2* in heavily iron-over-

loaded patients with beta-thalassemia major. Ann Hematol 2010; 89:4059.

Alkindi S, Al Zadjali S, Al Madhani A, Daar S, Al Haddabi H, Al Abri Q, Gravell D, Berbar T, Pravin S, Pathare A, Krishnamoorthy R. Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates.

Hemoglobin 2010; 34:13544.


3. 4. 5.

ease. Rheumatol Int 2010; Feb 4, [Epub ahead of print].

Alkaabi JK, Pathare A. Pattern and outcome of vascular involvement of Omani patients with Behcets dis-

Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer 2010; 55:4016. Alkindi S, Khan S, Riyami D, Farooqi M, Pathare A. Coexistence of immune thrombocytopenic purpura and

idiopathic membranous glomerulonephritis successfully treated with rituximab. Platelets 2010; 12 July. [Epub ahead of print]. tomy and thrombosis: the case of thalassaemia intermedia. J Thromb Haemost 2010; June [Epub ahead of print].
Taher A, Musallam K, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Age-related complications in treatmentnave patients with thalassemia intermedia. Br J Haem 2010; April [Epub ahead of print]. Taher AT, Musallam KM, Karimi M, El-Beshlawy A,Belhoul K, Daar S, Saned M, Cassaretti C, Cappellini M. Splenec-

7.

8. 9.

with deferasirox in iron-overloaded patients with thalassaemia: Results from the Escalator Trial. Acta Hematologica 2010; 123:2205.

Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience

10. Taher A, Musallam K, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview of practices in thalassemia

intermedia management aiming for lowering complication-rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115:188692.

96

11. Al-Khabori M, Minden MD, Yee KWL, et al. Improved survival using an intensive, pediatric-based chemother-

apy regimen in adults with T-cell acute lymphoblastic leukemia. Leukemia & Lymphoma 2010; 51:615.

12. Khabori MA, El-Emary M, W Xu, Guyatt G, et al. Impact of intensity of the conditioning therapy in patients

aged 40 to 60 years with acute myeloid leukemia/ myelodysplastic syndrome undergoing allogeneic transplantation. Bone Marrow Transplantation 2010; July [Epub ahead of print]. palsy: Asystematic review and meta-analysis. JAMA 2009; 302:98593.

13. de Almeida JR, Al Khabori M, Guyatt GH, et al. Combined corticosteroid and antiviral treatment for Bells 14. El-Emary M, Khabori MA, Buitron N, et al. Long term outcomes of allogeneic stem cell transplantation for

chronic lymphocytic leukemia. Biol Blood Marrow Transpl 2010; 16:S2756.

C O N F ER EN C E & SEM INA R P R E S E NT A T IO NS


Conference Presentations
International
1. Pathare AV, Al Zadjali S, Misquith R, Alkindi S, Dennison D, Pravin S, Berbar T, Krishnamoorthy R. Pharmacoge-

nomic variants of CYP2C9, CYP4F2 and VKORC1 and its relation to warfarin response in native Omani patients. 15th Congress of the European Hematology Association. Barcelona, Spain, 1013 June 2010.
Daar S, Al Salmi F, Ableen V, Jacob W, Jabeen Z, PathareA. T2* MRI- an effective tool to increase chelation com-

2.

Conference Posters
International
1. Al-Khabori MK, El-Emary M, Guyatt G, Galal A, Kuruvilla J, Lipton JH, et al. Impact of the intensity of condition-

ing therapy on the outcomes of patients aged 40 to 60 years with acute myeloidleukemia/myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. American Society of Haematology, Annual Meeting. New Orleans, USA, 58 December 2009. Pub. in: Blood (ASH Annual Meeting Abstracts) 2009; 114:1202.
Al-Khabori MK, Almeida J, Guyatt G, Kuruvilla J, Crump M. High dose chemotherapy and autologous stem cell

transplantation in the primary therapy of advanced follicular lymphoma in adults: A systematic review and meta-analysis of randomized clinical trials. American Society of Haematology, Annual Meeting. New Orleans, USA, 58 December 2009. Pub. in: Blood (ASH Annual Meeting Abstracts), 2009; 114:2314. (HLA) does not compromise outcomes in adults undergoing matched unrelated allogeneic bone marrow
Khabori MA, El-Emary M, Messner H, et al. Two-digit resolution typing of class-I human leukocyte antigen

3.

97

Haematology

2.

academic and patient care departments

pliance in thalassaemia major. 15th Congress of the European Hematology Association. Barcelona, Spain, 1013 June 2010.

Annual Report 2009-2010


Haematology
transplantation. Symposium of the American Society for Blood and Marrow Transplantation. Milano Italy, 2729 March 2009. Pub. in: Blood Marrow Transpl 2010; 16:S219.
4. AlMadhani A, Alkindi S, AlZadjali S, Misquith R, Pathare A, Krishnamoorthy R. Neonatal screening of newborns: Targeted versus universal approach as a cost effective strategy. 15th Congress European Hematology Association. Barcelona, Spain, 1013 June 2010. Ho CH, Gravell D. Can very high value of D-dimer predict the presence of thromboembolic disorders? 15th

5.

Congress of the European Hematology Association. Barcelona, Spain, 10-13 June 2010. Pub. in: Haematologica 2010; 95:292 (Abstract 699).
Taher A, Musallam K, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Age-related complications in treatmentnave patients with thalassemia intermedia. 15th Congress of the European Hematology Association. Barcelona, Spain, 1013 June 2010.

6.

7.

case of thalassaemia intermedia. 15th Congress of the European Hematology Association. Barcelona, Spain, 10-13 June 2010.
Pathare AV, Al Zadjali S, Misquith R, Alkindi S, Krishnamoorthy R. Pharmacogenomic variants of CYP2C9, CY-

Musallam K, Cappellini M, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Splenectomy and thrombosis: the

National
1.

P4F2 and VKORC1 and its relation to warfarin response in native Omani patients. University Day. Sultan Qaboos University, Muscat, Oman, 2 May 2009.

Seminar Presentations
International
1. 2. 3. 4. 1. 2. 3. Alkindi S. Sickle cell disease program at the Sultan Qaboos University Hospital, 1st Haematology Update Conference.

Manama, Bahrain, May 2010.

Daar S. Iron chelation in Beta thalasaemia, 1st Haematology Update Conference. Manama, Bahrain, May 2010. Daar S. Myocardial T2* MRI for Diagnosis & Follow-up of cardiac Siderosis in Thalassaemia; 1st Haematology Update Conference. Manama, Bahrain, May 2010. Daar S. Exjade The Oman Experience. Gulf Thalassaemia Workshop. Dubai, UAE, Feb 2010, Alkindi S. Update on CML, Crown Plaza, Muscat, Oman, November 2009. Alkindi S. Update on Current status of SCD in Oman. Advanced General Medical Conference, Sultan Qaboos Unviersity, Muscat, Oman, February 2010. Alkindi S. Comprehensive care of patients with Sickle cell disease, Sohar Hospital, Oman, March 2010.

National

98

4. 5. 6. 7.

Alkindi S. General overview of hereditary blood disorders, Hereditary Blood Disorder Society, Muscat, Oman, April 2010. Alkindi S. Update on Bortezomib. Grand Hyatt, Muscat, Oman, May 2010. Alkindi S. Laboratory Investigations & Management of thrombophilia. Ibra Hospital, Oman, May 2010. AlFarsi K. Clinical cases with thrombophilia. Oman Hematology Forum, Blood Club. Al Sawadi Hotel, Oman, Jan-

uary 2010.

academic and patient care departments

99

Haematology

Potrebbero piacerti anche